Drug shortages
Drug Shortage Tracker
Which medications are currently in short supply, from the FDA Drug Shortage Database, with the affected manufacturers.
Data updated 2026-05-15
- 71
- Active shortages
Data from the FDA Drug Shortage Database, updated as the FDA publishes changes. See our methodology.
PlainMeds tracks 71 active FDA drug shortages, showing which medications are in short supply, the affected manufacturers, and links to each drug profile.
A drug shortage means a medication is in short supply relative to demand, tracked in the FDA Drug Shortage Database. PlainMeds lists 71 currently active shortages with the affected products and manufacturers. A shortage may not affect every pharmacy or formulation, and the status changes as the FDA updates its database. Educational information, not medical advice.
71
Current Shortages
172
To Be Discontinued
5
Resolved
Showing 248 medications with shortage activity
Current Shortages (71)
To Be Discontinued (172)
Discontinuation of the manufacture of the drug
A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of private label only
A business decision was made to discontinue manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product to expire in March 2026; Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Supply is expected to be depleted by 12/31/2025.
A business decision was made to discontinue manufacture of the drug.
To be discontinued December 1, 2025
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.
Discontinuation of the manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug.
Business decision. Products will not be available after November 14, 2025.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.
The 10 mg presentation remains available.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug. Product expected to be available through July 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the product.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation is for the “NovaPlus” label product only.
A business decision was made to discontinue.
Discontinuation of the manufacture of the drug. Supply expected to exhaust September 2025
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product expected to be available until August 2025.
A business decision was made to discontinue manufacture of the product
Discontinuation of the manufacture of the drug
Permanent discontinuation in the manufacturing of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the product.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Permanent discontinuation
Permanent discontinuation
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation of manufacture due to business decision.
Permanent discontinuation of specific package size/ SKU for business reasons.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
Discontinuation of the manufacture of the drug.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Equivalent Sandoz format is available.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue.
Product is expected to be available through February 2027.
A business decision was made to discontinue manufacture of the drug.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuing manufacture of the product as of June 2026.
Discontinuation of the manufacture of the drug
The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
To be discontinued in approximately mid-2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Recently Resolved (5)
What to Do If Your Medication Is in Shortage
1. Contact Your Pharmacist
Your pharmacist can check other manufacturers and distributors for available supply.
2. Ask About Alternatives
Your prescriber can suggest therapeutic alternatives in the same drug class.
3. Don't Stockpile
Hoarding medications worsens shortages for everyone. Request only what you need.
Explore More
Frequently Asked Questions
What causes drug shortages?
How often is this data updated?
What should I do if my medication is in shortage?
Does a shortage mean I cannot get my medication?
Shortage Data Methodology
Shortage records are pulled directly from FDA Drug Shortages Database via the openFDA API. Status codes (Current, To Be Discontinued, Resolved), affected dosage forms, presentations, and manufacturer names are reproduced verbatim from FDA records. Therapeutic categories and brand-to-generic linkage leverage FDA SPL labels for cross-referencing. See the full methodology page for data vintage, processing pipeline, and interpretation caveats.
Disclaimer: This page provides information from the FDA Drug Shortages Database for educational purposes only. It is not medical advice. Always consult your healthcare provider or pharmacist about medication availability and alternatives. Do not stop or change any medication without professional guidance.